Cardior Pharmaceuticals Announces Positive Phase Ib Results of its Lead Compound CDR132L in Heart Failure

Hanover, Germany, November 12, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today positive results of a Phase Ib study with its lead compound CDR132L. The compound is an antisense oligonucleotide inhibiting the non-coding microRNA-132 (miR132) that directly regulates adverse cardiac remodeling. This first-in-human study was performed in cooperation with Richmond Pharmacology Ltd., London, UK (clinicaltrials.gov: NCT04045405). Results were published in the European Heart Journal (doi:10.1093/eurheartj/ehaa898).